Denali’s Avlayah Reduces CSF Heparan Sulfate by 91% in Phase 1/2 Trial for MPS II
Denali’s Avlayah reduced cerebrospinal fluid heparan sulfate by 91% in a Phase 1/2 trial for pediatric Hunter syndrome patients.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Health
January-February 2026 (vaccine recommendations, oral GLP-1 approvals, appropriations bill)
The CDC updated childhood vaccine guidelines, reducing routine immunizations from 17 to 11 diseases and shifting six vaccines to high-risk groups.
Read More
Would either of these alternatives be helpful?
Linguists and style experts explained that “alternative” implies mutually exclusive choices, while “option” denotes any selectable possibility.
Read More
Congress Enacts Most Favored Nation Pricing for Biologics and Specialty Drugs Amid State Price Controls
Congress enacted Most Favored Nation pricing for biologics and specialty drugs on May 12, 2025, aligning U.S. prices with lower international rates.
Read More
CMS Finalizes 2.6% Increase in Medicare Hospital Outpatient Payment Rates for CY 2026
CMS finalized a 2.6% increase in Medicare hospital outpatient payment rates for 2026, affecting 4,000 hospitals and 6,000 surgical centers.
Read More
Sarcopenic Obesity Combo Raises Death Risk 83%, New Study Warns of Belly Fat and Low Muscle Dangers
A study finds sarcopenic obesity, excess belly fat with low muscle, raises death risk by 83% in adults over 50.
Read More
FDA Proposes Reclassifying Mycobacterium Tuberculosis Immunity Tests to Class II Devices
The FDA proposed reclassifying Mycobacterium tuberculosis immunity tests from Class III to Class II devices with new special controls.
Read More
Simple Therapies Outperform Drugs in Major Analysis of 10,000 Knee Arthritis Patients
A global analysis of 10,000 knee arthritis patients found knee braces, water therapy, and exercise outperform drug treatments in pain relief and function.
Read More
FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24
The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.
Read More
FDA Approves Lifyorli (relacorilant) for Platinum-Resistant Ovarian Cancer on March 25
The FDA approved relacorilant (Lifyorli) with nab-paclitaxel for platinum-resistant ovarian cancer, based on improved progression-free survival in a phase 3 trial.
Read More